Literature DB >> 18175394

The pathogenesis of cell death in Parkinson's disease--2007.

C Warren Olanow1.   

Abstract

A number of factors have been implicated in the pathogenesis of cell death in Parkinson's disease (PD). These include oxidative stress, mitochondrial dysfunction, inflammation, excitotoxicity, and apoptosis. While the precise pathogenic mechanism leading to neurodegeneration in PD is not known, there is considerable evidence suggesting that cell death occurs by way of a signal-mediated apoptotic process. PD is also characterized by intracellular proteinaceous inclusions or Lewy bodies. Proteolytic stress arises as a consequence of the excessive production of misfolded proteins, which exceed the capacity of the ubiquitin-proteasome system to degrade them. Recent genetic and laboratory studies support the possible relevance of proteolytic stress to both familial and sporadic forms of PD. Postmortem studies have shown that in the SNc of sporadic PD patients there are reduced levels of the alpha subunit of the 20S proteasome and reduced proteolytic enzyme activities. A determination as to the precise cause of cell death in PD, and the identification of specific targets for the development of drugs that might modify disease progression is one of the most critical goals in PD research. It is anticipated that over the next few years there will be a flurry of scientific activity examining the mechanism of cell death and putative neuroprotective interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18175394     DOI: 10.1002/mds.21675

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  63 in total

1.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

Review 2.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

3.  Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway.

Authors:  Anthony K F Liou; Rehana K Leak; Lihua Li; Michael J Zigmond
Journal:  Neurobiol Dis       Date:  2008-07-08       Impact factor: 5.996

Review 4.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 5.  Rifampicin and Parkinson's disease.

Authors:  Wei Bi; Lihong Zhu; Xiuna Jing; Yanran Liang; Enxiang Tao
Journal:  Neurol Sci       Date:  2012-07-21       Impact factor: 3.307

6.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 7.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

8.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Laurel Macey; Lauren T Brown; Anna M Krichevsky; Susan L Andersen; Robert M Stephens; Francine M Benes; Kai C Sonntag
Journal:  Brain       Date:  2008-12-03       Impact factor: 13.501

Review 9.  The role of rasagiline in the treatment of Parkinson's disease.

Authors:  Julie Leegwater-Kim; Elena Bortan
Journal:  Clin Interv Aging       Date:  2010-05-25       Impact factor: 4.458

10.  Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease.

Authors:  Markos Poulopoulos; Cheryl Waters
Journal:  Core Evid       Date:  2010-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.